Loading Dose of Aztreonam-Avibactam in Pediatric Patients
A loading dose of aztreonam-avibactam should be administered in pediatric patients, following the same principle established for adults, though specific pediatric dosing data for this combination remains limited.
Rationale for Loading Dose Administration
The use of a loading dose is critical to rapidly achieve therapeutic concentrations, particularly in critically ill patients where the volume of distribution is often increased. 1 This principle applies regardless of whether continuous or intermittent infusion is used for maintenance dosing. 1
Pharmacokinetic Justification
The antibiotic concentration immediately after the loading dose depends on the volume of distribution, which is frequently increased in critically ill patients, especially those with multiple organ failures and increased capillary permeability. 1
Loading doses should be used for the first beta-lactam administration in all critically ill patients, independent of organ failure status or the continuous versus discontinuous administration method. 1
For aztreonam-avibactam specifically, population pharmacokinetic modeling demonstrated that loading doses support more rapid joint target attainment for both aztreonam (60% fT >8 mg/L) and avibactam (50% fT >2.5 mg/L). 2
Recommended Dosing Approach
Adult-Derived Principles Applied to Pediatrics
The approved adult regimen uses a 500/167 mg loading dose followed by 1500/500 mg maintenance infusions every 6 hours (3-hour infusions) for patients with creatinine clearance >50 mL/min. 2, 3
The loading dose should be identical to that used in discontinuous administration, followed by immediate start of maintenance infusion. 1
Pediatric Considerations
For aztreonam monotherapy in pediatric patients, the FDA-approved dosing is 30 mg/kg every 6-8 hours for moderate to severe infections (maximum 120 mg/kg/day). 4
Given the 3:1 fixed ratio of aztreonam-avibactam, pediatric loading doses should follow this same ratio principle, with the loading dose equivalent to one maintenance dose. 2, 3
Aztreonam should be administered intravenously to pediatric patients with normal renal function, as there are insufficient data regarding intramuscular administration or dosing in pediatric patients with renal impairment. 4
Critical Implementation Points
Timing and Administration
The loading dose achieves target concentrations more rapidly than maintenance dosing alone, which is particularly important in serious infections. 2
Continuous infusion preceded by a loading dose achieves the greatest percentage of time above MIC compared to intermittent administration or continuous infusion without loading. 1
Renal Function Adjustments
The total daily maintenance dose should be adjusted according to creatinine clearance, while always using a loading dose corresponding to a unitary dose as used during discontinuous administration in patients without kidney failure. 1
For pediatric patients with renal impairment, there are insufficient data to guide specific dosing adjustments for aztreonam-avibactam. 4
Common Pitfalls to Avoid
Do not omit the loading dose in an attempt to reduce drug waste—early exposure is critical for optimal outcomes, and the transient impact of dose reduction compromises pharmacokinetic/pharmacodynamic performance. 5
Do not assume that continuous infusion alone without a loading dose will achieve adequate concentrations—the concentration may remain below MIC for several hours after beginning infusion without a loading dose. 1
Recognize that pediatric patients under 9 months of age have limited safety and efficacy data for aztreonam, and no specific data exist for aztreonam-avibactam in this age group. 4